[{"id":"a67aed5e-970a-42cd-bd14-2f95cb2cc1c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05082610","created_at":"2021-10-19T16:56:14.467Z","updated_at":"2025-02-25T16:16:48.554Z","phase":"Phase 1","brief_title":"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05082610","lead_sponsor":"Hummingbird Bioscience","biomarkers":" EGFR • PD-L1 • ALK • PD-1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • PD-L1 • ALK • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • HMBD-002"],"overall_status":"Recruiting","enrollment":" Enrollment 313","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-10-23"}]